EUVIMEDEUVIMED entdecken
Crossref

A Novel Synbiotic Protects Against DSS-Induced Colitis in Mice via Anti-inflammatory and Microbiota-Balancing Properties

Yong Yang, Yuyu Qiao, Ge Liu, Weihao Chen, Ting Zhang, Jing Liu, Weiping Fan, Mingwei Tong

Probiotics and Antimicrobial Proteins · 2025

DOI: 10.1007/s12602-024-10393-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Probiotics and Antimicrobial Proteins, 2025. Verfasst von Yong Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, China. Hauptthemen laut MEDLINE: Synbiotics, Anti-Inflammatory Agents, Colitis, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanxi Province, cience Research Start-up Fund for Doctor of Shanxi Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD) is a chronic immune-inflammatory disease. Gut microbes, intestinal immunity, and gut barrier function play a critical role in IBD. Growing evidence suggests that synbiotic may offer therapeutic benefits for individuals with colitis, suggesting an alternative therapy against colitis. With this in mind, we creatively prepared a new synbiotic combination consisting of a probiotic strain (Limosilactobacillus reuteri) along with one prebiotic chitooligosaccharides (COS). The protective effects of the synbiotic on DSS-induced colitis and the underlying mechanisms were investigated. We demonstrated that the synbiotic ameliorated colitis in mice, as evidenced by a significant remission in body weight loss and colon shortening, and a decreased disease activity index (DAI). Notably, synbiotic reduced the intestinal inflammation and injury by synergistically decreasing inflammatory factors, inhibiting TLR4/Myd88/NF-κB/NLRP3 signaling, preventing macrophage infiltration, and enhancing the integrity of the intestinal barrier. Moreover, synbiotic selectively promoted the growth of beneficial bacteria (e.g., Akkermansia, Lactobacillus) but decreased the pathogenic bacteria (e.g., Helicobacter). BugBase's analysis supported its ameliorated role in reducing pathogenic bacteria. Collectively, our findings revealed the novel synbiotic had a potential to treat colitis, which was associated with its anti-inflammatory and microbiota-balancing properties. This study will contribute to the development of functional synbiotic products for IBD therapy and will provide valuable insights into their mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SynbioticsAnti-Inflammatory AgentsColitisInflammatory Bowel DiseasesGastrointestinal MicrobiomeDextran SulfateLimosilactobacillus reuteriOligosaccharidesChitosanIntestinal Barrier FunctionMaleAnimalsMiceMice, Inbred C57BL

Stichwörter der Autor:innen

Gut barrier functionGut microbiotaInflammatory bowel diseaseIntestinal inflammationSynbiotic

Substanzen

Anti-Inflammatory AgentsDextran SulfateoligochitosanOligosaccharidesChitosan

Autor:innen und Institutionen

  • School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, China.
  • Key Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of Education, and, Shanxi Key Laboratory of Cellular Physiology , Taiyuan, 030001, China.
  • Department of Ruminant Nutrition, Institute of Special Animal and Plant Sciences, Chinese Academy of Agricultural Sciences, Changchun, 130112, China.
  • Department of Endocrinology, Second Hospital of Shanxi Medical University, Taiyuan, China. jingliu@sxmu.edu.cn.
  • School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, China. fanweiping26418@126.com.
  • Key Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of Education, and, Shanxi Key Laboratory of Cellular Physiology , Taiyuan, 030001, China. fanweiping26418@126.com.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shanxi Province
  • cience Research Start-up Fund for Doctor of Shanxi Medical University

Zitieren

APA

Yang, Y., Qiao, Y., Liu, G., Chen, W., Zhang, T., Liu, J., Fan, W., & Tong, M. (2025). A Novel Synbiotic Protects Against DSS-Induced Colitis in Mice via Anti-inflammatory and Microbiota-Balancing Properties. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-024-10393-2

Vancouver

Yang Y, Qiao Y, Liu G, Chen W, Zhang T, Liu J, et al. A Novel Synbiotic Protects Against DSS-Induced Colitis in Mice via Anti-inflammatory and Microbiota-Balancing Properties. Probiotics and Antimicrobial Proteins. 2025. doi:10.1007/s12602-024-10393-2

BibTeX
@article{Yang2025,
  author = {Yang, Yong and Qiao, Yuyu and Liu, Ge and Chen, Weihao and Zhang, Ting and Liu, Jing and Fan, Weiping and Tong, Mingwei},
  title = {A Novel Synbiotic Protects Against DSS-Induced Colitis in Mice via Anti-inflammatory and Microbiota-Balancing Properties},
  journal = {Probiotics and Antimicrobial Proteins},
  year = {2025},
  doi = {10.1007/s12602-024-10393-2}
}
Kostenlos starten →